Business context and reporting period
Summit Therapeutics plc’s Form 20-F is an audited annual report for the fiscal year ended January 31, 2019—not a report for calendar-quarter 2018 Q4. The company is a UK-incorporated, clinical-stage biotechnology company focused on antibiotics. Its financial statements are prepared under IFRS and presented in pounds sterling; U.S. dollar figures are convenience translations.
The lead candidate, ridinilazole, is being developed for Clostridium difficile infection (CDI). The company also has a preclinical gonorrhea candidate, SMT-571, and discovery-stage programs against ESKAPE pathogens. Summit discontinued its Duchenne muscular dystrophy program after ezutromid failed its Phase 2 trial.
Financial performance and liquidity
| Metric | FY ended Jan. 31, 2019 | FY ended Jan. 31, 2018 |
|---|---|---|
| Revenue | £43.012 million | £12.360 million, adjusted for IFRS 15 |
| Other operating income | £15.156 million | £2.725 million |
| Research and development expense | £39.174 million | £28.970 million |
| General and administrative expense | £12.342 million | £11.999 million |
| Operating profit/(loss) | £2.667 million | (£25.884 million) |
| Net profit/(loss) | £7.527 million | (£20.190 million) |
| Operating cash flow | (£26.795 million) | (£14.689 million) |
| Cash and cash equivalents at year-end | £26.858 million | £20.102 million |
FY2019 reported profit was not a reliable indicator of recurring operating performance: following ezutromid’s discontinuation, Summit recognized the remaining deferred revenue under its Sarepta collaboration. The company states this recognition did not generate cash. Sarepta-related revenue was £42.3 million, including £6.3 million of cost-share income. There is no product-sales revenue reported.
At January 31, 2019, total assets were £59.767 million, total liabilities £17.225 million, and equity £42.542 million. Working capital was £7.007 million. Financial liabilities on funding arrangements were nil at year-end; the filing does not report conventional borrowings outstanding. Investing cash outflow was £0.313 million and financing cash inflow was £33.437 million, principally from equity issuance. No dividend was declared or paid.
Material changes versus the prior comparable year
- Revenue rose by £30.652 million, and Summit moved from an operating and net loss to reported profit, principally because the discontinued Sarepta program’s deferred revenue was recognized in full.
- Other operating income increased to £15.156 million, largely reflecting £13.091 million recognized under the BARDA contract.
- Research and development expense increased 35% to £39.174 million, including higher CDI trial preparation and manufacturing expenditure; DMD spending fell after ezutromid was discontinued.
- Summit recorded a £3.985 million impairment charge, writing off the remaining utrophin-program intangible asset and related MuOx goodwill.
- Operating cash outflow increased by £12.106 million to £26.795 million. Summit attributed the change to higher operating costs, lower net cash receipts from licensing and funding arrangements, and timing of research-and-development tax-credit receipts.
- The company adopted IFRS 15 retrospectively. The FY2018 comparative was restated: revenue and profit were each reduced by £13.059 million. Comparisons should use the adjusted figures shown in the filing.
- Equity financing materially expanded the share base: 86.458 million ordinary shares were issued during FY2019, including shares underlying the January 2019 ADS placement. Year-end ordinary shares outstanding were 160.390 million.
Outlook, risks and unusual items
- Ridinilazole’s two Phase 3 trials began dosing in February 2019, after manufacturing challenges delayed their planned start. Summit expected top-line results from both trials in the second half of 2021. The primary endpoint is superiority to vancomycin in sustained clinical response.
- Management estimated existing cash and expected funding—including committed BARDA funding, initial CARB-X funding and Sarepta cost sharing—would fund operations and capital expenditure through January 31, 2020. Summit stated that additional capital would be required to complete the Phase 3 trials. The estimate depends on assumptions and funding availability.
- The auditor highlighted the need for additional financing. The financial statements disclose a material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern; they contain no adjustments for a possible failure to continue as a going concern.
- BARDA had committed $44 million of a contract potentially worth up to $62 million; remaining options are discretionary. CARB-X awarded up to $4.5 million, of which $2.0 million was initially funded and the balance depended on options and milestones.
- Key execution risks include clinical-trial efficacy and safety, rapid CDI patient enrollment, tablet-form manufacturing and third-party supply, regulatory approval, and dependence on external funding and collaborators. Most pipeline programs remain preclinical or discovery stage.
- Commercial risks include competition from generic vancomycin and metronidazole and approved fidaxomicin, as well as uncertain reimbursement, pricing and market acceptance. Summit had no established sales organization.
- Summit reported that U.S. investor Robert W. Duggan owned approximately 48.81% of outstanding share capital as of March 1, 2019, following the January placement. His shares were subject to a lock-up, with resale registration rights also disclosed.
- Management reported effective disclosure controls and internal control over financial reporting as of January 31, 2019. The auditor did not provide an internal-control attestation because Summit was an emerging growth company.
Important facts for investors to verify
- Whether the reported FY2019 profit is understood in light of the noncash release of Sarepta deferred revenue and whether it recurs.
- Cash runway assumptions, actual BARDA and CARB-X receipts, remaining option exercises, and the timing and terms of additional financing.
- Phase 3 enrollment progress, trial results and any further manufacturing or supply delays for ridinilazole.
- The effect of the January 2019 financing and subsequent share issuances on dilution, ownership concentration and potential resale supply.
- The carrying value and future development milestones supporting the Discuva Platform intangible asset, and the status and funding needs of SMT-571 and the ESKAPE program.